William Yang, MD
Nephrology · Northridge, CANPI 1609005479
Payments from drug & device makers
Across 1,075 payments — averaging $231.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$158K
- AstraZeneca$61K
- Vifor Pharma, Inc.$11K
- Amgen$3K
- Daiichi Sankyo Inc.$2K
- Scpharmaceuticals Inc.$2K
- plus $11K from 29 others
What the payments were for
- Speaking & faculty fees$43,63766%
- Travel & lodging$360%
- Food & beverage$22,15033%
- Education$3551%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 147 | $157,859 |
| AstraZeneca(2 entities) | 90 | $61,144 |
| Vifor Pharma, Inc. | 102 | $11,410 |
| Amgen(2 entities) | 178 | $3,366 |
| Daiichi Sankyo Inc. | 100 | $2,179 |
| Scpharmaceuticals Inc. | 5 | $2,068 |
| Otsuka America Pharmaceutical, Inc. | 64 | $1,587 |
| Lilly USA, LLC | 60 | $1,211 |
| CSL Behring | 4 | $1,068 |
| Novo Nordisk | 47 | $786 |
| Akebia Therapeutics Inc | 38 | $777 |
| Novartis | 37 | $709 |
| Johnson & Johnson | 34 | $665 |
| Boehringer Ingelheim | 26 | $648 |
| Amarin Pharma, Inc. | 30 | $646 |
| Mallinckrodt Hospital Products Inc. | 26 | $610 |
| Mallinckrodt Enterprises LLC | 10 | $373 |
| GSK | 14 | $325 |
| Cipla USA Inc. | 2 | $299 |
| Aurinia Pharma U.S., Inc. | 11 | $237 |
| Travere Therapeutics, Inc. | 7 | $143 |
| Ardelyx, Inc. | 5 | $140 |
| Fresenius USA Marketing, Inc. | 5 | $110 |
| Currax Pharmaceuticals LLC | 6 | $100 |
| Calliditas Therapeutics US Inc. | 5 | $97 |
| Lexicon Pharmaceuticals, Inc. | 3 | $90 |
| OPKO Pharmaceuticals, LLC | 4 | $89 |
| Boston Scientific | 2 | $87 |
| Sanofi | 4 | $75 |
| Merck | 3 | $49 |
| Arbor Pharmaceuticals, Inc. | 2 | $42 |
| ANI Pharmaceuticals, Inc. | 1 | $33 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$249,084 in reported general payments places this provider in the 90th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tolvaptan | 87 | $239,805 |
| KerendiaFinerenone | 170 | $221,744 |
| JynarqueTolvaptan | 11 | $203,226 |
| JardianceEmpagliflozin | 138 | $182,581 |
| OzempicSemaglutide | 83 | $129,708 |
| FarxigaDapagliflozin Propanediol | 117 | $118,616 |
| MounjaroTirzepatide | 79 | $96,789 |
| VeltassaPatiromer Calcium Sorbitex | 94 | $81,595 |
| RybelsusSemaglutide | 23 | $43,527 |
| TrulicityDulaglutide | 27 | $42,917 |
| XphozahTenapanor Hcl | 14 | $39,616 |
| LokelmaSodium Zirconium Cyclosilicate | 42 | $38,147 |
| ProcritEpoetin Alfa | 32 | $35,294 |
| EntrestoSacubitril/Valsartan | 21 | $34,255 |
| RayaldeeCalcifediol | 23 | $29,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerKerendia | $157,859 | $221,744170 claims |
| Otsuka America Pharmaceutical, Inc.Jynarque | $1,587 | $203,22611 claims |
| Boehringer IngelheimJardiance | $648 | $182,581138 claims |
| Novo NordiskOzempic, Rybelsus | $786 | $173,235106 claims |
| AstraZenecaFarxiga, Lokelma | $61,144 | $156,763159 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,211 | $139,705106 claims |
| Johnson & JohnsonProcrit | $665 | $35,29432 claims |
| NovartisEntresto | $709 | $34,25521 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $89 | $29,41823 claims |
| MerckJanuvia | $49 | $16,35313 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $33 | $1,95774 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,341 nephrology providers in California.
Other nephrology in Northridge
- Sohan DuaNorthridge$3.2M
- Ram PatakNorthridge$2M
- Dayan GandhiNorthridge$1M
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Richard LafayetteStanford$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.